Drug intelligence / Profile preview

2-selenocyano-3-methoxyestradiol-17-benzoate

Development stage: Preclinical
Lead developer: Guangxi Normal University
Modality: Small Molecules

Overview

2-selenocyano-3-methoxyestradiol-17-benzoate (compound 7e) is a synthetic steroidal selenocyanate derivative investigated for its antitumor properties. It is synthesized by introducing a selenocyano group at the 2-position of the estradiol scaffold, with additional methoxy and benzoate modifications. In preclinical studies, compound 7e demonstrated selective inhibitory activity against HeLa cervical cancer cell lines with an IC50 of 4.1 µM, primarily by inducing programmed apoptosis. Furthermore, it has shown efficacy in vivo by significantly inhibiting the growth of human cervical cancer xenografts in zebrafish models.

Other names: 2-selenocyano-3-methoxyestradiol-17-benzoate

Beyond the preview

Go deeper on 2-selenocyano-3-methoxyestradiol-17-benzoate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-selenocyano-3-methoxyestradiol-17-benzoate.

Explore the full profile